Company Overview and News


Add SAN
to your dashboard

Headline News

Will Europe buyouts help Indian drug makers counter US pricing pressure?

2018-01-12 moneycontrol
At least four Indian drug makers including Aurobindo Pharma, Cadila Healthcare, Torrent Pharma and Intas are said to be eyeing the generic business put on block by French pharmaceutical group Sanofi, according to a report in Economic Times. (2-0)

ECB Leaves Interest Rate Unchanged: ETFs in Focus

2017-12-15 zacks
The European Central Bank (ECB) kept its key interest rate unchanged in its latest policy meeting in December, the last for this calendar year.   (4-0)

Sanofi Pasteur exec: Dengvaxia is ‘a safe and efficacious vaccine’

2017-12-11 newsinfo.inquirer.net
An official from Sanofi Pasteur, manufacturer of Dengvaxia dengue vaccine, has denied negligence on the part of the company, saying that permanently removing the vaccine from the Philippine market would be a disservice to Filipinos.

Sanofi (SNY) a Hold on Vapid Earnings Momentum

2017-12-08 investorplace
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe.

Pain or Promise: Where Brexit Matters Most

2017-12-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (24-0)

Trial results of Zika vaccine Sanofi dropped show promise

2017-12-05 reuters
CHICAGO (Reuters) - A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday.

Filipinos not made guinea pigs – Sanofi

2017-12-05 newsinfo.inquirer.net
EMPTY VIALS At the Manila Central Vaccine storage room in Santa Cruz, Manila, are empty vials of the dengue vaccine Dengvaxia given to schoolchildren in the city. The drug producer, Sanofi Pasteur Philippines, says the vaccine does not contain viruses that can cause severe dengue. —EDWIN BACASMAS

WRAPUP 2-Trouble mounts for Sanofi dengue vaccine over safety concerns

2017-12-04 reuters
(Reuters) - The World Health Organization said on Monday it hopes to review safety data on Sanofi’s dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases.

Sanofi ends development of C. difficile vaccine

2017-12-01 channelnewsasia
Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

UPDATE 1-Sanofi ends development of C. difficile vaccine

2017-12-01 reuters
(Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

Sanofi ends development of Clostridium difficile vaccine - Channel NewsAsia

2017-12-01 channelnewsasia
Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

Robust Quant Score Metrics Drive Ranking of Sanofi (SNY) to Buy

2017-12-01 investorplace
Sanofi SA (NYSE:SNY) is one of the 781 companies in the GICS Health Care sector, and a member of the 134 company Pharmaceuticals GICS industry group within this sector. The market value of SNY is $115.8 billion which falls in the top decile in its industry group. The ranking for SNY by Portfolio Grader places it 34 among the 134 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 206 among the 781 companies in the sector, and number 1,262 in the nearly 5,000 company Portfolio Grader universe.

Biogen boosts multiple sclerosis holding with Alkermes license - Channel NewsAsia

2017-11-27 channelnewsasia
REUTERS: Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera. (67-0)

Biogen boosts multiple sclerosis holding with Alkermes license

2017-11-27 reuters
(Reuters) - Biogen Inc said on Monday it has licensed Alkermes Plc’s multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera. (67-0)

Sanofi (SNY) Earnings Growth Hurt Rating

2017-11-24 investorplace
Portfolio Grader currently ranks Sanofi SA (NYSE:SNY) a Hold. The system for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. SNY has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.